Reclast (Zoledronic Acid) Cost in Pennsylvania: 2026 Pricing, Insurance, and Savings Guide

Pending qualified medical review.

Reclast is the brand name for zoledronic acid 5 mg/100 mL, an intravenous bisphosphonate FDA-approved for treatment and prevention of postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, and Paget disease of bone. A generic version has been available for years, per the FDA's own drug approval database. This is a different drug and a different dose from the 4 mg zoledronic acid used in oncology (Zometa), which is dosed far more frequently for bone metastases and hypercalcemia of malignancy. Confirm which formulation and indication apply before comparing any price.

What is established: zoledronic acid for osteoporosis is normally given as a single IV infusion once a year, it is covered under Medicare Part B (not Part D) because it is physician-administered, and a generic exists alongside brand Reclast. What is not established in this draft: a reliable, current, Pennsylvania-specific cash price. Published "average" cash prices for infused specialty drugs change by pharmacy, infusion site, and month, and no primary source in this review supports a specific 2026 Pennsylvania dollar figure. Readers should treat any single number, including ones seen elsewhere online, as a starting estimate to be confirmed with the actual billing site, not a guaranteed price.

Why a precise Pennsylvania price cannot be stated here

Drug pricing for infused specialty medications depends on the payer contract, the site of administration (hospital outpatient department versus freestanding infusion center versus home infusion), whether the patient is on Medicare, Medicaid, or commercial insurance, and whether a 340B-eligible facility is involved. These variables shift by month and by contract renewal, not just by state. A prior version of this page stated specific cash-pay figures and insurance copay ranges for Pennsylvania. Those figures could not be verified against a primary source in this review and have been removed rather than repeated. If you need an actual number, the reliable path is to call the specific pharmacy or infusion center and your insurer, not to rely on a published national average attributed to your state.

The manufacturer's public list price for brand-name drugs is also not the same as what any individual pays, since list price does not reflect rebates, discounts, or your specific plan's negotiated rate.

How Medicare Part B covers zoledronic acid

For Pennsylvania residents on Original Medicare, zoledronic acid administered by a physician or in an outpatient setting is billed under Medicare Part B as an infused drug rather than through a Part D pharmacy benefit. Under standard Part B rules, the beneficiary is generally responsible for coinsurance after the annual Part B deductible is met, with the remainder covered by Medicare; a Medigap supplement can offset that coinsurance for many enrollees. The exact percentage, deductible amount, and any site-of-care differential can change from year to year, so confirm the current-year figures with Medicare or your plan rather than relying on a fixed percentage stated elsewhere. Medicare Advantage plans (including Pennsylvania-based carriers) cover zoledronic acid under the medical benefit as well, but prior authorization timelines and documentation requirements are plan-specific and should be confirmed directly with the plan. General Medicare drug-coverage policy for physician-administered drugs is described in CMS's published payment guidance, which readers should look up directly.

How Pennsylvania Medicaid approaches coverage

Pennsylvania Medicaid, like most state Medicaid programs, requires prior authorization for higher-cost infused osteoporosis drugs when a cheaper oral bisphosphonate has not been tried or is contraindicated. The kind of clinical documentation typically requested for osteoporosis drug prior authorization, generally, includes evidence meeting the standard clinical definition of osteoporosis (a bone density T-score at or below −2.5, or a history of a fragility fracture) and a documented reason the patient cannot use an oral bisphosphonate, such as intolerance, an esophageal disorder, or inability to remain upright after dosing. These are general clinical thresholds used across guidelines, not a confirmed transcription of Pennsylvania's current Preferred Drug List criteria. The exact current Pennsylvania Medicaid prior authorization form, the specific managed care organizations operating in the state, and their individual step-therapy rules change over time and were not independently verified for this draft. Contact the Pennsylvania Department of Human Services or the specific Medicaid managed care plan directly, and keep a copy of any denial for a possible grievance or fair hearing.

Commercial insurance: what is likely stable, what is not

Most major commercial insurers licensed in Pennsylvania cover zoledronic acid for its FDA-approved indications, since covering FDA-approved standard-of-care osteoporosis treatment is typical of commercial formulary design. What is not stable, and was not independently verified for this draft, is the specific formulary tier, copay amount, or coinsurance percentage for any particular plan. Tier placement for specialty infused generics and brand products changes at least annually with formulary updates. Ask your insurer's member services line for the current tier and estimated cost share for the specific NDC (generic or brand) your prescriber intends to order, before scheduling the infusion.

Discount and assistance programs: what exists and what to confirm

• Manufacturer patient assistance and copay support. Brand-name drug manufacturers commonly offer patient assistance programs for uninsured or underinsured patients and copay cards for commercially insured patients. As a matter of federal anti-kickback rules, these copay programs are generally not usable by patients covered by Medicare, Medicaid, or other federal health programs. Confirm current eligibility criteria and savings amounts directly with the manufacturer's program, since income thresholds and card values are updated periodically and were not independently verified here.
• 340B pricing at qualifying facilities. Hospitals and clinics that participate in the federal 340B Drug Pricing Program purchase certain outpatient drugs, including many infused specialty products, at a discounted acquisition cost. Whether that discount is passed through to an individual patient's bill depends on the facility's own charity-care and billing policies, which vary by site. General program information is available from the Health Resources and Services Administration's 340B program page. Ask a specific Pennsylvania hospital or federally qualified health center whether it participates and how it applies 340B savings to self-pay patients.
• Site-of-care choice. Freestanding infusion centers sometimes bill lower facility fees than hospital outpatient departments for the same drug, but this is not universal and should be confirmed with a direct quote from each site rather than assumed.

Verification checklist: what is stable versus what you must re-check

Use this before scheduling an infusion or appealing a denial. The left column is unlikely to change month to month. The right column changes with contracts, plan years, and local billing practices, and should be re-verified close to your infusion date.

If a claim you were told (by a call center, a search result, or a prior version of this article) does not appear in the left column with a primary source, treat it as unverified until you confirm it directly with the payer or facility involved.

Compounded zoledronic acid: legal status and cautions

A 503A compounding pharmacy may legally prepare zoledronic acid under the Drug Quality and Security Act if you have a valid, patient-specific prescription. Unlike the FDA-approved Reclast infusion or its generic versions, compounded zoledronic acid does not receive FDA premarket approval and lacks the same manufacturing controls, per FDA consumer guidance on compounding. The standard osteoporosis regimen for zoledronic acid (5 mg/100 mL once yearly) is fixed, so compounding's main advantage of providing non-standard doses or formulations is limited here compared to drugs with more variable dosing needs. Before pursuing a compounded version for cost reasons, verify that the pharmacy holds a current Pennsylvania license, follows USP sterile compounding standards, and confirm whether your insurance plan will cover it; many insurers including Medicare and Medicaid decline reimbursement when an FDA-approved alternative exists.

Telehealth prescribing in Pennsylvania

A clinician can evaluate bone density results, fracture history, and relevant labs by telehealth and issue a prescription remotely; Pennsylvania has telehealth-specific statutory provisions, though the exact current scope and insurer parity requirements should be checked at the state legislature's site rather than assumed to be unchanged from any prior year. The infusion itself is not a telehealth service: it must be administered in person at a clinic, hospital outpatient department, or home infusion service, typically after pre-infusion labs (serum calcium, vitamin D, and a kidney-function measure) are drawn locally.

How zoledronic acid compares to alternatives on dosing, not price

Dosing frequency is a stable, label-based fact and a legitimate way to compare burden across osteoporosis drugs, even where price comparisons are not reliable enough to state precisely:

• Oral bisphosphonates (for example, weekly alendronate) require weekly or daily adherence, sitting upright after dosing, and are generally the lowest-acquisition-cost class, though adherence has been reported as a real-world problem in the osteoporosis literature.
• Zoledronic acid (Reclast and generics) is dosed once yearly by IV infusion for osteoporosis, removing daily or weekly adherence burden but requiring an infusion visit and pre-dose kidney function screening.
• Denosumab (Prolia) is a subcutaneous injection given every six months. Discontinuing denosumab without transitioning to another antiresorptive has been associated with an increased fracture risk, including vertebral fracture, in reported clinical experience, which is a materially different discontinuation risk profile than bisphosphonates and worth discussing with a prescriber regardless of cost.
• Romosozumab (Evenity) is a monthly anabolic injection given for a fixed 12-month course, generally reserved for patients at very high fracture risk, with a bisphosphonate (often zoledronic acid) commonly used afterward to maintain bone density gains.

This article does not include specific efficacy claims for zoledronic acid such as fracture reduction percentages or mortality benefits, because earlier citations could not be confirmed through review of original trial reports. When a prescriber presents such numbers during your discussion, ask them to reference the current FDA label or the underlying trial evidence for that claim.

When to seek care rather than manage this by cost alone

Cost strategy should not delay evaluation of a new fracture, sudden bone pain, jaw pain or numbness after a recent dental procedure (a rare but recognized bisphosphonate-associated concern), or symptoms of very low calcium (muscle cramps, tingling around the mouth or fingers) after an infusion. Those situations warrant prompt contact with the prescribing clinician or urgent care rather than waiting on an insurance appeal or discount program.